Sign in along with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to love Gabe Cole?s video.
Sign in along with your Google Account (YouTube, Google+, Gmail, Orkut, Picasa, or Chrome) to dislike Gabe Cole?s video.
Uploaded on Aug 30, 2011
Orange County real estate investor and Realtor Gabe Cole presents two different investment strategies to exploit the opportunities in today?s real estate market. The longer term buy and hold have been proven time and time again as a super long run wealth builder. The Fannie Mae Homepath program is a wonderful opportunity to buy investment property with less money out of pocket.
The short term buy and flip model continues to be alive and well and Gabe shows you the method he?s implementing with a few of his clients to make the most and profit in with this model.
Should you could have any questions or would really like additional info about real estate and investing, be at liberty to contact Gabe Cole at 949.395.4223 or visit his website at www.gabecolerealestate.com.
Loading?
Loading?
Loading?
The interactive transcript couldn?t be loaded.
Loading?
Loading?
Ratings has been disabled for this video.
Rating is out there when the video have been rented.
This feature isn?t available at this time. Please try again later.
This entry was posted on Friday, June 28th, 2013 at 7:19 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
After Great Dane success, cancer doc eyes brain tumorsPublic release date: 27-Jun-2013 [ | E-mail | Share ]
Contact: Garth Sundem garth.sundem@ucdenver.edu University of Colorado Denver
2 University of Colorado Cancer Center publications set stage for K9 cancer vaccine test with human glioblastoma
Michael Graner, PhD, is a CU Cancer Center investigator and associate professor of neurosurgery at the CU School of Medicine. So when his 12-year-old Great Dane got sick, he knew what to do.
"We got Star from the Mid-Atlantic Great Dane Rescue," Graner says. "She got her name because she was always smiling, like a movie star waiting for photos. She'd already been to so many shelters, we didn't want to change her name again and so we kept it."
At 12, after many years with the Graners, Star had already reached about double the average lifespan for the breed. When she collapsed during a coughing fit, Graner discovered the cause: lung cancer, specifically advanced bronchoalveolar adenocarcinoma with metastasis to the lymph nodes. The prognosis was grim, with a median survival from diagnosis of only about 6-27 days. And Star was well past the age when she could've tolerated chemotherapy or radiation.
"With that diagnosis, chemotherapy has only a 10-15 percent response rate and she was old with her prognosis and the drug side effects let's just say chemotherapy wasn't viable. We didn't want to make her any sicker," Graner says.
So he turned to his specialty, immunotherapy. The idea is to circumvent the immune system's nasty habit of recognizing cancer as its own tissue instead of seeing it as an invading disease and attacking it. By using engineered vaccines to prime the immune system to recognize tumors, cancer immunologists are using the body's own defenses to clear itself of the disease. In this case, the treatment was fairly simple and carried almost no chance of side effects that could make Star any less comfortable: a 10-gram sample of her tumor was enriched into an injectable vaccine that contained a high concentration of heat shock proteins in "chaperone-rich cell lysate" (CRCL), which tell the immune system's T-cells what to attack.
"We expected to see solid metastases within days," said Graner. "But, you know, then the months started to go by. The important thing to us was her quality of life was really good. It was really simple and it certainly didn't hurt." You can read about the treatment and results in a paper in the International Journal of Hyperthermia, on which Graner collaborated with Laura Epple, DVM, now a PhD candidate in the Graner Lab.
Finally, at 44 weeks more than ten times the best they should have hoped for! Star showed aggressive progression of the disease. At nearly a year after the diagnosis of a disease that should have killed her within a month, Graner and his family made the difficult decision to euthanize Star.
"We still have a couple of her cell lines here in the lab," Graner says. "In that way, she's kind of immortal."
Another chance for Star's immortality comes from her potential for her experience to extend the lives of human brain cancer patients. See, Graner has continued his studies with the CRCL-rich vaccines of the type that led to Star's dramatic and prolonged improvement.
"It's one thing to treat mice in these fake systems and another to treat a naturally arising tumor that had a poor prognosis," Graner says. Along with Kevin Lellehei, chair of Neurosurgery at the University of Colorado School of Medicine, Graner recently submitted a proposal to the FDA to treat human glioblastoma with CRCL vaccine. "Star's success may make it much easier for the FDA to approve similar treatment with human glioblastoma," Graner says.
In Graner's proposed trial, human brain cancer patients would continue to receive the standard of care to treat the disease and would also intersperse treatment with the experimental vaccine, whose benefit he hopes to show, but which is also unlikely to cause additional harm.
He describes a similar protocol that failed to get approval from the European Medicines Agency.
"This isn't a brand new idea," Graner says. "But until now there had been some gaps in our understanding." One of these gaps was the fact that while previous researchers had hypothesized that tumor chaperone proteins carried the peptides that, when enriched and reinjected as a vaccine, could sensitize the immune system to tumor tissues, previous studies hadn't identified these peptides.
In another recent paper, also published in the International Journal of Hyperthermia, Graner describes what he calls, "taking these proteins and beating the peptides off them to see what they are." Sure enough, many of the peptides isolated from tumor samples were derived from proteins unique to cancer this means that a CRCL vaccine was likely to result in an immune response directed specifically at tumor tissue and not at surrounding, healthy tissues.
Graner writes that, "Parental proteins [that would be targets for the immune cells] are components of major signaling networks of vital importance for cancer cell survival, proliferation, and migration."
With the immune system sensitized, the unique genetic mutations that allow cancer cells to act cancerous would also mark them for destruction. With this research gap filled and with Star demonstrating the vaccine's effect, Graner is hopeful his proposed trial will make it to human patients soon.
"She was a real sweetie," Graner says of Star. "Hopefully her contribution to the world has just begun."
###
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
After Great Dane success, cancer doc eyes brain tumorsPublic release date: 27-Jun-2013 [ | E-mail | Share ]
Contact: Garth Sundem garth.sundem@ucdenver.edu University of Colorado Denver
2 University of Colorado Cancer Center publications set stage for K9 cancer vaccine test with human glioblastoma
Michael Graner, PhD, is a CU Cancer Center investigator and associate professor of neurosurgery at the CU School of Medicine. So when his 12-year-old Great Dane got sick, he knew what to do.
"We got Star from the Mid-Atlantic Great Dane Rescue," Graner says. "She got her name because she was always smiling, like a movie star waiting for photos. She'd already been to so many shelters, we didn't want to change her name again and so we kept it."
At 12, after many years with the Graners, Star had already reached about double the average lifespan for the breed. When she collapsed during a coughing fit, Graner discovered the cause: lung cancer, specifically advanced bronchoalveolar adenocarcinoma with metastasis to the lymph nodes. The prognosis was grim, with a median survival from diagnosis of only about 6-27 days. And Star was well past the age when she could've tolerated chemotherapy or radiation.
"With that diagnosis, chemotherapy has only a 10-15 percent response rate and she was old with her prognosis and the drug side effects let's just say chemotherapy wasn't viable. We didn't want to make her any sicker," Graner says.
So he turned to his specialty, immunotherapy. The idea is to circumvent the immune system's nasty habit of recognizing cancer as its own tissue instead of seeing it as an invading disease and attacking it. By using engineered vaccines to prime the immune system to recognize tumors, cancer immunologists are using the body's own defenses to clear itself of the disease. In this case, the treatment was fairly simple and carried almost no chance of side effects that could make Star any less comfortable: a 10-gram sample of her tumor was enriched into an injectable vaccine that contained a high concentration of heat shock proteins in "chaperone-rich cell lysate" (CRCL), which tell the immune system's T-cells what to attack.
"We expected to see solid metastases within days," said Graner. "But, you know, then the months started to go by. The important thing to us was her quality of life was really good. It was really simple and it certainly didn't hurt." You can read about the treatment and results in a paper in the International Journal of Hyperthermia, on which Graner collaborated with Laura Epple, DVM, now a PhD candidate in the Graner Lab.
Finally, at 44 weeks more than ten times the best they should have hoped for! Star showed aggressive progression of the disease. At nearly a year after the diagnosis of a disease that should have killed her within a month, Graner and his family made the difficult decision to euthanize Star.
"We still have a couple of her cell lines here in the lab," Graner says. "In that way, she's kind of immortal."
Another chance for Star's immortality comes from her potential for her experience to extend the lives of human brain cancer patients. See, Graner has continued his studies with the CRCL-rich vaccines of the type that led to Star's dramatic and prolonged improvement.
"It's one thing to treat mice in these fake systems and another to treat a naturally arising tumor that had a poor prognosis," Graner says. Along with Kevin Lellehei, chair of Neurosurgery at the University of Colorado School of Medicine, Graner recently submitted a proposal to the FDA to treat human glioblastoma with CRCL vaccine. "Star's success may make it much easier for the FDA to approve similar treatment with human glioblastoma," Graner says.
In Graner's proposed trial, human brain cancer patients would continue to receive the standard of care to treat the disease and would also intersperse treatment with the experimental vaccine, whose benefit he hopes to show, but which is also unlikely to cause additional harm.
He describes a similar protocol that failed to get approval from the European Medicines Agency.
"This isn't a brand new idea," Graner says. "But until now there had been some gaps in our understanding." One of these gaps was the fact that while previous researchers had hypothesized that tumor chaperone proteins carried the peptides that, when enriched and reinjected as a vaccine, could sensitize the immune system to tumor tissues, previous studies hadn't identified these peptides.
In another recent paper, also published in the International Journal of Hyperthermia, Graner describes what he calls, "taking these proteins and beating the peptides off them to see what they are." Sure enough, many of the peptides isolated from tumor samples were derived from proteins unique to cancer this means that a CRCL vaccine was likely to result in an immune response directed specifically at tumor tissue and not at surrounding, healthy tissues.
Graner writes that, "Parental proteins [that would be targets for the immune cells] are components of major signaling networks of vital importance for cancer cell survival, proliferation, and migration."
With the immune system sensitized, the unique genetic mutations that allow cancer cells to act cancerous would also mark them for destruction. With this research gap filled and with Star demonstrating the vaccine's effect, Graner is hopeful his proposed trial will make it to human patients soon.
"She was a real sweetie," Graner says of Star. "Hopefully her contribution to the world has just begun."
###
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Numerous cultures believe that the world is borne atop a monumental animal deity?be it the Iroquois' Great Turtle or the World Serpents and Elephants from Hindu mythology?so why not a Great Elk?
The animation team at awesome and modest produced this hypnotic visual interpretation to Pete Van Leeuwen's subtle song.
WASHINGTON (AP) ? Social Security is approving disability benefits at strikingly high rates for people whose claims were rejected by field offices or state agencies, according to House investigators. Compounding the situation, the agency often fails to do required follow-up reviews months or years later to make sure people are still disabled.
Claims for benefits have increased by 25 percent since 2007, pushing the fund that supports the disability program to the brink of insolvency, which could mean reduced benefits. Social Security officials say the primary driver of the increase is demographic, mainly a surge in baby boomers who are more prone to disability as they age but are not quite old enough to qualify for retirement benefits.
The disability program has been swamped by benefit claims since the recession hit a few years ago. Last year, 3.2 million people applied for Social Security Disability or Supplemental Security Income.
In addition, however, management problems "lead to misspending" and add to the financial ills of the program, investigators from the House Oversight and Government Reform Committee say.
"Federal disability claims are often paid to individuals who are not legally entitled to receive them," three senior Republicans on the House committee declared in a March 11 letter to the agency. Among the signers was the committee's chairman, Rep. Darrell Issa of California.
Social Security acknowledges a backlog of 1.3 million overdue follow-up reviews to make sure people still qualify for benefits. But agency officials blame budget cuts for the backlog, saying Congress has denied the funds needed to clear it.
Social Security spokesman Mark Hinkle said the agency follows the strict legal definition of disability when awarding benefits. In order to qualify, a person is supposed to have a disability that prevents him from working and is expected to last at least a year or result in death.
"Even with this very strict standard, there has been growth in the disability program, and the primary reason for this growth is demographics," Hinkle said. He noted that approval rates have declined as applications for benefits have increased.
The most common claimed disability was bone and muscle pain, including lower back pain, followed closely by mental disorders, according to the program's latest annual report.
"Pain cases and mental cases are extremely difficult because ? and even more so with mental cases ? there's no objective medical evidence," said Randall Frye, a Social Security administrative law judge in Charlotte, N.C. "It's all subjective."
Nearly 11 million disabled workers, spouses and children get Social Security disability benefits. That's up from 7.6 million a decade ago. The average monthly benefit for a disabled worker is $1,130.
An additional 8.3 million people get Supplemental Security Income, a separately funded disability program for low-income people.
If Congress doesn't act, the trust fund that supports Social Security disability will run out of money in 2016, according to projections by Social Security's trustees. At that point, the system will collect only enough money in payroll taxes to pay 80 percent of benefits, triggering an automatic 20 percent cut in benefits.
Congress could redirect money from Social Security's much bigger retirement program to shore up the disability program, as it did in 1994. But that would worsen the finances of the retirement program, which is facing its own long-term financial problems.
The House oversight subcommittee on entitlements is scheduled to hold the first of several hearings on the disability program Thursday. The hearing will focus on the role of administrative law judges in awarding benefits.
Most Social Security disability claims are initially processed through a network of local Social Security Administration field offices and state agencies, usually Disability Determination Services, and most are rejected. If your claim is rejected, you can ask the field office or state agency to reconsider. If your claim is rejected again, you can appeal to an administrative law judge, who is employed by Social Security.
The hearing process takes an average of a little more than a year, according to Social Security statistics. The agency estimates there are 816,000 hearings pending.
So far this budget year, the vast majority of judges have approved benefits in more than half the cases they've decided, even though they were reviewing applications that had typically been rejected twice by state agencies, according to Social Security data.
Of the 1,560 judges who have decided at least 50 cases since October, 195 judges approved benefits in at least 75 percent of their cases, according to the data, which were analyzed by congressional investigators.
"This is not one or two judges out there just going rogue and saying they are going to approve a lot of cases," said Rep. James Lankford, R-Okla., chairman of the House Oversight Subcommittee on Energy, Policy, Health Care, and Entitlements. "This is a very, very high rate" of approving claims.
The union representing administrative law judges says judges are required to decide 500 to 700 cases a year in an effort to reduce the hearings backlog. The union says the requirement is an illegal quota that leads judges to sometimes award benefits they might otherwise deny just to keep up with the flow of cases, according to a federal lawsuit filed by the judges' union in April.
"I wouldn't want to suggest publicly that judges are not following the law or the regulations," said Frye, the North Carolina law judge who also is president of the Association of Administrative Law Judges , But, he added, "Would you want your surgeon to be on a quota system, to have to do so many surgeries every morning? Mistakes are going to be made when you force that kind of system on professional folks whose judgment, skill and experience are critical to coming to a good result."
The agency denies there is a case quota for judges, saying the standard is a productivity goal. The agency has declined to comment on the lawsuit. Former Social Security Commissioner Michael Astrue said he set the goal in 2007 to help reduce the hearings backlog.
Once people get benefits, their cases are supposed to be reviewed periodically to make sure they are still disabled. The reviews are called continuing disability reviews, or CDRs.
For people whose disabilities are expected to improve, CDRs should be done in six to 18 months, according a 2010 report by the agency's inspector general. If improvement is possible ? but not necessarily likely ? reviews should be done every three years. People with disabilities believed to be permanent should get reviews every five to seven years.
At the end of 1996, there was a backlog of 4.3 million overdue reviews. In response, Congress authorized about $4 billion to fund a seven-year effort to wipe it out, and the backlog was erased in 2002.
But after the funding dried up, the number of annual reviews performed by the agency decreased and the backlog grew. Last year, the agency conducted 443,000 continuing reviews.
President Barack Obama's proposed budget for next year includes $1.5 billion to address the backlog, a nearly 50 percent increase over present funding. With the increase, the agency says it would be able to conduct slightly more than 1 million reviews.
"We have completed every CDR funded by Congress, but our administrative budget has been significantly reduced, resulting in three straight years of funding levels nearly a billion dollars below the president's budget requests," Hinkle said. "As a result, we have lost more than 10,000 employees since the beginning of (fiscal year) 2011. We currently have a backlog of 1.3 million CDRs, which we would be able to address with adequate, dedicated program integrity funding from Congress."
___
Follow Stephen Ohlemacher on Twitter: http://twitter.com/stephenatap
BERLIN (AP) ? German authorities are investigating two men of Tunisian origin suspected of planning to use model airplanes for terrorist attacks, prosecutors said Tuesday, as police in Germany and Belgium raided a series of sites searching for evidence of "possible attack plans and preparations."
No one was arrested in Tuesday's raids, which were carried out in the Stuttgart and Munich areas of southern Germany and in Saxony in eastern Germany, federal prosecutors said in a statement. One site in Belgium was raided, German officials said without elaborating.
Prosecutors said the investigation involved possible charges of "preparation of a serious, state-threatening act of violence," but they did not mention membership in any specific terrorist organization.
The two Tunisians are suspected of "procuring information and objects to commit Islamic extremist explosive attacks with remote-controlled model airplanes," prosecutors added. They gave no further information on the two men and didn't identify them.
However, the public broadcaster in southwestern Germany, SWF, quoted unnamed sources as saying that the two were studying aeronautics in Stuttgart and were suspected of trying to develop techniques for remotely piloting model planes using GPS technology.
German authorities would not say whether the alleged plot was far advanced, but the German news agency, quoting unnamed security sources, said the suspects had been under surveillance for more than a year.
The agency said authorities had recently detected "an increased interest in explosives and model aircraft."
However, authorities added that the national terror threat had not been raised, suggesting police believe the alleged plan ? if there were one ? was in early stages.
Among the locations raided were the apartments of four acquaintances of the two men who were suspected of financing Islamic extremism, officials said. The investigation also targeted another acquaintance suspected of money laundering. None of the suspects was identified.
Last November, a U.S. man, Rezwan Ferdaus, was sentenced to 17 years in prison over a plot to fly remote-controlled model planes packed with explosives into the Pentagon and U.S. Capitol.
Last year, Spanish police released a video they claimed showed suspected al-Qaida members training for a bombing raid using a model plane. Two Russians of Chechen origin were charged with possession of explosives but were released in April for lack of evidence. A Turk living in Spain was also arrested but later released.
Germany has seen only one successful attack by an Islamic radical ? the fatal shooting of two U.S. airmen at Frankfurt airport in 2011 by a Kosovo native who grew up in Germany and became radicalized by watching jihadist propaganda on the Internet.
However, there have been several attempted attacks in the country, which is a major contributor to international forces in Afghanistan.
Separately Tuesday, French authorities said police detained six people in the Paris region on suspicion of plotting terrorist attacks in France.
Sheri was the first (fake) victim on the "Whodunnit?" premiere.
As the premiere episode of ABC's reality TV murder mystery "Whodunnit?" opened Sunday night, a voiceover explained that the contestants knew they were there to play a game, but "what they don't know is: The game is murder."
As it turned out, the contestants weren't the only ones who didn't quite know all the details. For instance, viewers knew the show was a murder mystery, but it's now clear what many of them didn't know was that the murders weren't real.
That's right, despite the fact that killing off contestants would be illegal (and, of course, just plain wrong), some believed that two players might have actually been killed as part of the show.
Concerned viewers even took to Twitter after the first person, Sheri, met her (not really) final fate.
Even after contestant Melina said, "In my heart, I know it's not a dead body, but it feels too real," some viewers remained suspicious.
When Dontae fled the "Whodunnit?" mansion in flames at the end of the show, even more shocked viewers tweeted their fears.
Of course, there was no need to worry about anyone. The mystery -- not the murder -- is the reality in this competition.
Check out the next faux fatalities when "Whodunnit?" airs Sunday night at 9 p.m. on ABC.
Like 
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uzHgp5WPfKDoU-3QLfrIN93VbfUPb4PStU0BJd6UbEURX7_zUNKFiFGMnE-FBMDPMrc_0ogPfO6c8IZfrdSMFSOInzF3Qpynna_VJi6LA=s0-d){kind=small}
Public release date: 27-Jun-2013
Share ] 
